Charles River Labs Divests CDMO & European Discovery Assets, Boosts EPS Guidance

summarizeSummary

Charles River Laboratories announced two strategic divestitures, selling its CDMO and Cell Solutions businesses and certain European Discovery Services assets, which are expected to improve non-GAAP EPS and operating margins for 2026.

check_boxKey Events

• Divestiture of CDMO & Cell Solutions Businesses

  The company signed a definitive agreement to divest its contract development and manufacturing products and services (CDMO) and Cell Solutions businesses to GI Partners for future, contingent performance-based payments. These businesses generated combined annual revenue of $143 million in 2025.

• Sale of European Discovery Services Assets

  Charles River Laboratories also signed a definitive agreement to divest certain European assets within its Discovery Services business to IQVIA Holdings Inc. for approximately $145 million in cash, plus potential additional payments up to $10 million. These assets generated $144 million in 2025 annual revenue.

• Updated 2026 Financial Guidance

  The company updated its 2026 financial guidance, initially provided on February 18, 2026, to reflect the impact of the planned divestitures. The transactions are expected to reduce reported revenue by slightly more than $200 million, but generate at least 100 basis points of incremental non-GAAP operating margin improvement and add approximately $0.10 to non-GAAP earnings per share for the partial year.

auto_awesomeAnalysis

This 8-K details significant strategic divestitures by Charles River Laboratories, aiming to streamline operations and enhance profitability. The sale of the CDMO and Cell Solutions businesses, along with specific European Discovery Services assets, represents a substantial realignment of the company's portfolio. While these divestitures will reduce reported revenue, the updated 2026 guidance indicates an expected increase in non-GAAP earnings per share and a notable improvement in operating margin, suggesting a positive impact on the company's financial efficiency and focus on higher-value segments. Investors should monitor the successful completion of these transactions and the company's performance against the revised guidance.